Galymzhan Togizbayev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Galymzhan Togizbayev has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Chokan Baimukhamedov
South Kazakhstan Medical Academy, Shymkent, Kazakhstan
4 shared publications - Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
3 shared publications - Pawel Pludowski
Department of Clinical Biochemistry, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland
3 shared publications - Abdimutalib Mamasaidov
Osh State University
2 shared publications - Danagul Maksot
Kazakh National Medical University named after S.D. Asfendiyarov
2 shared publications - Dildora Abdumalikovna Nabieva
Tashkent Medical Academy
2 shared publications
Latest Publications
- 23 October 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (10)
Development and Preliminary Psychometric Validation of the Gout Knowledge, Attitudes and Practices (G‐KAP) Questionnaire: An Asia‐Pacific Multicenter Study
Aim: To develop and undertake preliminary psychometric validation of the Gout Knowledge, Attitudes and Practices (G‐KAP) Questionnaire for patients with gout in multiple Asia‐Pacific clinical settings. Methods: Six development experts and nine relevance experts reviewed the English 56‐question instrument. Analyses included 312 baseline participants from 10 countries and 117 paired assessments; 149 participants formed an additional recruitment‐wave subset. Language assistance involved oral explanation without a fixed translation script. We evaluated content relevance, keyed knowledge reliability, item‐level stability, and exploratory structure using explicit coding and missing‐data rules. Results: S‐CVI/Ave was 0.998 across 68 rated rows. The 19‐indicator knowledge score averaged 56.1% ± 20.3%; KR‐20 was 0.770 and common‐factor omega 0.764. Absolute‐agreement single‐measure ICC was 0.763 (95% bootstrap CI 0.635–0.857); mean retest increase was 2.34 percentage points ( p = 0.037). Numeric attitude ICCs ranged 0.345–0.838. Among 303 complete cases for 38 exploratory indicators, full‐matrix and common‐factor parallel analyses suggested 7 and 11 dimensions. The seven‐factor comparison model included two weak two‐item factors and ambiguous cross‐loadings. Conclusion: The English G‐KAP shows strong expert‐rated relevance and encouraging preliminary knowledge‐score reliability. Oral‐assistance variability, unequal recruitment and uncertain dimensionality limit interpretation. Cross‐cultural validity, measurement invariance, attitude/practice composite scores and clinical effectiveness are unestablished. Standardized administration, linguistic adaptation and independent confirmatory evaluation are needed before cross‐country comparison or subscale development.
- 23 October 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (10)
Development and Preliminary Psychometric Validation of the Gout Knowledge, Attitudes and Practices (G‐KAP) Questionnaire: An Asia‐Pacific Multicenter Study
Aim: To develop and undertake preliminary psychometric validation of the Gout Knowledge, Attitudes and Practices (G‐KAP) Questionnaire for patients with gout in multiple Asia‐Pacific clinical settings. Methods: Six development experts and nine relevance experts reviewed the English 56‐question instrument. Analyses included 312 baseline participants from 10 countries and 117 paired assessments; 149 participants formed an additional recruitment‐wave subset. Language assistance involved oral explanation without a fixed translation script. We evaluated content relevance, keyed knowledge reliability, item‐level stability, and exploratory structure using explicit coding and missing‐data rules. Results: S‐CVI/Ave was 0.998 across 68 rated rows. The 19‐indicator knowledge score averaged 56.1% ± 20.3%; KR‐20 was 0.770 and common‐factor omega 0.764. Absolute‐agreement single‐measure ICC was 0.763 (95% bootstrap CI 0.635–0.857); mean retest increase was 2.34 percentage points ( p = 0.037). Numeric attitude ICCs ranged 0.345–0.838. Among 303 complete cases for 38 exploratory indicators, full‐matrix and common‐factor parallel analyses suggested 7 and 11 dimensions. The seven‐factor comparison model included two weak two‐item factors and ambiguous cross‐loadings. Conclusion: The English G‐KAP shows strong expert‐rated relevance and encouraging preliminary knowledge‐score reliability. Oral‐assistance variability, unequal recruitment and uncertain dimensionality limit interpretation. Cross‐cultural validity, measurement invariance, attitude/practice composite scores and clinical effectiveness are unestablished. Standardized administration, linguistic adaptation and independent confirmatory evaluation are needed before cross‐country comparison or subscale development.
- Open Access
Expert Consensus on Optimizing the Strategy for the Prevention of Vitamin D Deficiency in Central Asia: From Scientific Evidence to Real-World Practice
Background/Objectives: Vitamin D deficiency and insufficiency represent a widespread problem in the majority of Central Asian countries, attributable to the geographical location of the region, urbanization, and dietary patterns of the population. Given that vitamin D not only participates in the regulation of calcium and phosphate metabolism but also exerts pleiotropic effects on various organs and systems, its insufficiency and deficiency are associated with a broad spectrum of pathological conditions, ranging from asymptomatic manifestations to severe clinical symptoms, including the development of autoimmune diseases, metabolic disorders, cardiovascular, gynecological and reproductive, and rheumatological conditions. The development of national and interdisciplinary guidelines addressing the diagnosis, prevention of insufficiency, and correction of vitamin D deficiency in the countries of Central Asia represents an important step toward the establishment of effective preventive programs and treatment strategies, which may contribute to a reduction in the prevalence of diseases associated with vitamin D deficiency. The aim of the present work is to formulate a resolution capturing the conclusions and recommendations derived from an interdisciplinary expert discussion. Methods: An Expert Council meeting with the participation of specialists in endocrinology, obstetrics and gynecology, rheumatology, clinical pharmacology, and other medical disciplines from Central Asian and European countries was conducted in Almaty (Kazakhstan) on 18 June 2025. During this meeting, the pleiotropic action of vitamin D was extensively discussed basing on RCTs and observational studies. Results: Following the Expert Council meeting, current international clinical guidelines, scientific research data, and relevant epidemiological evidence were reviewed, leading to the formulation of a resolution that reflects the agreed-upon recommendations for the prevention of vitamin D insufficiency and the correction of vitamin D deficiency across different age groups according to baseline vitamin D metabolite levels. Conclusions: The expert discussion emphasized the need for unified interdisciplinary approaches to the diagnosis, correction, and prevention of vitamin D deficiency in the countries of Central Asia. The proposed recommendations may serve as a foundation for the development of national clinical protocols and the implementation of effective preventive and therapeutic strategies in the countries of Central Asia.
Open AccessExpert Consensus on Optimizing the Strategy for the Prevention of Vitamin D Deficiency in Central Asia: From Scientific Evidence to Real-World Practice
Background/Objectives: Vitamin D deficiency and insufficiency represent a widespread problem in the majority of Central Asian countries, attributable to the geographical location of the region, urbanization, and dietary patterns of the population. Given that vitamin D not only participates in the regulation of calcium and phosphate metabolism but also exerts pleiotropic effects on various organs and systems, its insufficiency and deficiency are associated with a broad spectrum of pathological conditions, ranging from asymptomatic manifestations to severe clinical symptoms, including the development of autoimmune diseases, metabolic disorders, cardiovascular, gynecological and reproductive, and rheumatological conditions. The development of national and interdisciplinary guidelines addressing the diagnosis, prevention of insufficiency, and correction of vitamin D deficiency in the countries of Central Asia represents an important step toward the establishment of effective preventive programs and treatment strategies, which may contribute to a reduction in the prevalence of diseases associated with vitamin D deficiency. The aim of the present work is to formulate a resolution capturing the conclusions and recommendations derived from an interdisciplinary expert discussion. Methods: An Expert Council meeting with the participation of specialists in endocrinology, obstetrics and gynecology, rheumatology, clinical pharmacology, and other medical disciplines from Central Asian and European countries was conducted in Almaty (Kazakhstan) on 18 June 2025. During this meeting, the pleiotropic action of vitamin D was extensively discussed basing on RCTs and observational studies. Results: Following the Expert Council meeting, current international clinical guidelines, scientific research data, and relevant epidemiological evidence were reviewed, leading to the formulation of a resolution that reflects the agreed-upon recommendations for the prevention of vitamin D insufficiency and the correction of vitamin D deficiency across different age groups according to baseline vitamin D metabolite levels. Conclusions: The expert discussion emphasized the need for unified interdisciplinary approaches to the diagnosis, correction, and prevention of vitamin D deficiency in the countries of Central Asia. The proposed recommendations may serve as a foundation for the development of national clinical protocols and the implementation of effective preventive and therapeutic strategies in the countries of Central Asia.
- Open Access
- 26 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70752
2024 Update of the Asia‐Pacific League of Associations for Rheumatology ( APLAR ) Recommendations for Rheumatoid Arthritis Management
Aim: To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods: A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier studies where relevant. Recommendations were formulated based on this evidence and refined through a modified‐Delphi process during a series of online meetings. The quality of evidence and strength of recommendations were assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Results: This update comprises 14 statements that achieved consensus during the meetings. Topics covered include measurement of disease activity and treatment response, the use of conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), the use of targeted therapies, vaccination and screening for infections and the use of DMARDs during pregnancy. The recommendations address the selection of disease activity scores, initiation and intensification of therapy using csDMARDs and targeted therapies, and management of RA in patients at risk of reactivation of infectious diseases. These recommendations are discussed in the context of the clinical landscape encountered in the Asia‐Pacific region. Conclusion: These updated recommendations complement previous APLAR guidelines and aim to support best practice management of RA across the Asia‐Pacific region. They provide a practical framework for national rheumatology associations to develop local guidelines adapted to their specific needs and clinical practice.
- 26 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70752
Open Access2024 Update of the Asia‐Pacific League of Associations for Rheumatology ( APLAR ) Recommendations for Rheumatoid Arthritis Management
Aim: To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods: A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier studies where relevant. Recommendations were formulated based on this evidence and refined through a modified‐Delphi process during a series of online meetings. The quality of evidence and strength of recommendations were assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Results: This update comprises 14 statements that achieved consensus during the meetings. Topics covered include measurement of disease activity and treatment response, the use of conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), the use of targeted therapies, vaccination and screening for infections and the use of DMARDs during pregnancy. The recommendations address the selection of disease activity scores, initiation and intensification of therapy using csDMARDs and targeted therapies, and management of RA in patients at risk of reactivation of infectious diseases. These recommendations are discussed in the context of the clinical landscape encountered in the Asia‐Pacific region. Conclusion: These updated recommendations complement previous APLAR guidelines and aim to support best practice management of RA across the Asia‐Pacific region. They provide a practical framework for national rheumatology associations to develop local guidelines adapted to their specific needs and clinical practice.
- 15 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (6) , e70731
Severe Antisynthetase Syndrome ( ASS )–Spectrum Overlap Presenting With an Adult‐Onset Still's–Like Phenotype and Complicated by Acute Exacerbation of Nonspecific Interstitial Pneumonia ( NSIP )–Pattern Connective Tissue Disease–Associated Interstitial Lung Disease ( CTD ‐ ILD )
- 15 June 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (6) , e70731
Severe Antisynthetase Syndrome ( ASS )–Spectrum Overlap Presenting With an Adult‐Onset Still's–Like Phenotype and Complicated by Acute Exacerbation of Nonspecific Interstitial Pneumonia ( NSIP )–Pattern Connective Tissue Disease–Associated Interstitial Lung Disease ( CTD ‐ ILD )
- 6 February 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (2) , e70566
Clinical Recommendations of the Qazaq College of Rheumatology for the Diagnosis and Treatment of Rheumatoid Arthritis: 2025 National Initiative
- 6 February 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (2) , e70566
Clinical Recommendations of the Qazaq College of Rheumatology for the Diagnosis and Treatment of Rheumatoid Arthritis: 2025 National Initiative
- 28 January 2026
- Published by Semey Medical University in Наука и здравоохранение
- No. 6(27),p. 212-219
QUALITY OF LIFE AND MENTAL HEALTH OF PATIENTS WITH RHEUMATOID ARTHRITIS. LITERATURE REVIEW
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease marked by persistent inflammation, joint damage, pain, and progressive functional limitations. These symptoms substantially reduce patients’ health-related quality of life (HRQoL), affecting physical functioning, emotional well-being, social participation, and work capacity. In addition to physical impairment, RA is strongly associated with mental health problems. Depression, anxiety, chronic stress, and sleep disturbances occur significantly more often in RA patients than in the general population. Psychological distress not only develops as a reaction to chronic pain and disability but also contributes to increased disease activity, heightened pain perception, and reduced adherence to treatment. The relationship between mental health and quality of life in RA is complex and bidirectional: poor psychological well-being worsens physical outcomes, while disease progression further aggravates emotional difficulties. Understanding this interplay is essential for developing effective biopsychosocial management strategies. This review summarizes current evidence on the quality of life and mental health of individuals with RA and identifies key factors influencing these outcomes. Aim. To review current literature on the quality of life and mental health of patients with rheumatoid arthritis, identifying key determinants and the interplay between psychological status and health-related quality of life. Search strategy. A literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar using keywords: “rheumatoid arthritis,” “quality of life,” “mental health,” “depression,” “anxiety,” “HRQoL.” Inclusion criteria: articles published in the last 10 years, in English, focused on adult RA populations. Narrative review methodology was applied. Results and conclusions. Evidence shows that reduced quality of life in RA is strongly associated with pain, functional limitations, fatigue, and psychological distress. Depression and anxiety are reported in up to one-third of patients and substantially worsen disease outcomes. Multidisciplinary management - including optimized pharmacotherapy, patient education, psychological support, and physical activity – d emonstrates effectiveness in improving both mental health and quality of life. Further research is needed to develop integrated biopsychosocial interventions. Введение: Ревматоидный артрит (РА) — хроническое аутоиммунное заболевание, характеризующееся стойким воспалением, повреждением суставов, болью и прогрессирующими функциональными ограничениями. Эти симптомы существенно снижают качество жизни, связанное со здоровьем (HRQoL), влияя на физическое функционирование, эмоциональное благополучие, социальную активность и трудоспособность. Помимо физических нарушений, РА тесно связан с проблемами психического здоровья. Депрессия, тревога, хронический стресс и нарушения сна встречаются у пациентов с РА значительно чаще, чем в общей популяции. Психологический дистресс формируется не только как реакция на хроническую боль и инвалидизацию, но и способствует повышению активности заболевания, усилению восприятия боли и снижению приверженности лечению. Взаимосвязь психического здоровья и качества жизни при РА является сложной и двусторонней: ухудшение психологического состояния негативно отражается на физических исходах, тогда как прогрессирование заболевания усиливает эмоциональные трудности. Понимание этих взаимодействий имеет ключевое значение для разработки эффективных биопсихосоциальных стратегий ведения пациентов. Настоящий обзор обобщает современные данные о качестве жизни и психическом здоровье пациентов с РА и выявляет ключевые факторы, влияющие на эти показатели. Цель. Проанализировать современную литературу, посвящённую качеству жизни и психическому здоровью пациентов с ревматоидным артритом, определить ключевые детерминанты и взаимосвязь психологического статуса с качеством жизни, связанным со здоровьем. Стратегия поиска. Поиск литературы проводился в базах PubMed, Scopus, Web of Science и Google Scholar с использованием ключевых слов: «rheumatoid arthritis», «quality of life», «mental health», «depression», «anxiety», «HRQoL». Критерии включения: статьи, опубликованные за последние 10 лет, на английском языке, посвящённые взрослой популяции пациентов с РА. Использовался нарративный...
- 28 January 2026
- Published by Semey Medical University in Наука и здравоохранение
- No. 6(27),p. 212-219
QUALITY OF LIFE AND MENTAL HEALTH OF PATIENTS WITH RHEUMATOID ARTHRITIS. LITERATURE REVIEW
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease marked by persistent inflammation, joint damage, pain, and progressive functional limitations. These symptoms substantially reduce patients’ health-related quality of life (HRQoL), affecting physical functioning, emotional well-being, social participation, and work capacity. In addition to physical impairment, RA is strongly associated with mental health problems. Depression, anxiety, chronic stress, and sleep disturbances occur significantly more often in RA patients than in the general population. Psychological distress not only develops as a reaction to chronic pain and disability but also contributes to increased disease activity, heightened pain perception, and reduced adherence to treatment. The relationship between mental health and quality of life in RA is complex and bidirectional: poor psychological well-being worsens physical outcomes, while disease progression further aggravates emotional difficulties. Understanding this interplay is essential for developing effective biopsychosocial management strategies. This review summarizes current evidence on the quality of life and mental health of individuals with RA and identifies key factors influencing these outcomes. Aim. To review current literature on the quality of life and mental health of patients with rheumatoid arthritis, identifying key determinants and the interplay between psychological status and health-related quality of life. Search strategy. A literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar using keywords: “rheumatoid arthritis,” “quality of life,” “mental health,” “depression,” “anxiety,” “HRQoL.” Inclusion criteria: articles published in the last 10 years, in English, focused on adult RA populations. Narrative review methodology was applied. Results and conclusions. Evidence shows that reduced quality of life in RA is strongly associated with pain, functional limitations, fatigue, and psychological distress. Depression and anxiety are reported in up to one-third of patients and substantially worsen disease outcomes. Multidisciplinary management - including optimized pharmacotherapy, patient education, psychological support, and physical activity – d emonstrates effectiveness in improving both mental health and quality of life. Further research is needed to develop integrated biopsychosocial interventions. Введение: Ревматоидный артрит (РА) — хроническое аутоиммунное заболевание, характеризующееся стойким воспалением, повреждением суставов, болью и прогрессирующими функциональными ограничениями. Эти симптомы существенно снижают качество жизни, связанное со здоровьем (HRQoL), влияя на физическое функционирование, эмоциональное благополучие, социальную активность и трудоспособность. Помимо физических нарушений, РА тесно связан с проблемами психического здоровья. Депрессия, тревога, хронический стресс и нарушения сна встречаются у пациентов с РА значительно чаще, чем в общей популяции. Психологический дистресс формируется не только как реакция на хроническую боль и инвалидизацию, но и способствует повышению активности заболевания, усилению восприятия боли и снижению приверженности лечению. Взаимосвязь психического здоровья и качества жизни при РА является сложной и двусторонней: ухудшение психологического состояния негативно отражается на физических исходах, тогда как прогрессирование заболевания усиливает эмоциональные трудности. Понимание этих взаимодействий имеет ключевое значение для разработки эффективных биопсихосоциальных стратегий ведения пациентов. Настоящий обзор обобщает современные данные о качестве жизни и психическом здоровье пациентов с РА и выявляет ключевые факторы, влияющие на эти показатели. Цель. Проанализировать современную литературу, посвящённую качеству жизни и психическому здоровью пациентов с ревматоидным артритом, определить ключевые детерминанты и взаимосвязь психологического статуса с качеством жизни, связанным со здоровьем. Стратегия поиска. Поиск литературы проводился в базах PubMed, Scopus, Web of Science и Google Scholar с использованием ключевых слов: «rheumatoid arthritis», «quality of life», «mental health», «depression», «anxiety», «HRQoL». Критерии включения: статьи, опубликованные за последние 10 лет, на английском языке, посвящённые взрослой популяции пациентов с РА. Использовался нарративный...
- Open Access
- 28 August 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (4) , 96-110
Eurasian recommendations for the diagnosis and treatment of primary osteoarthritis (2025). League of Eurasian Rheumatologists (LEAR)
These guidelines represent the official 2025 recommendations of the League of Eurasian Rheumatologists (LEAR) for the diagnosis and management of primary osteoarthritis. The recommendations were developed with participation of leading experts in Russia, Kazakhstan, Kyrgyzstan, and Uzbekistan.
- 28 August 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (4) , 96-110
Open AccessEurasian recommendations for the diagnosis and treatment of primary osteoarthritis (2025). League of Eurasian Rheumatologists (LEAR)
These guidelines represent the official 2025 recommendations of the League of Eurasian Rheumatologists (LEAR) for the diagnosis and management of primary osteoarthritis. The recommendations were developed with participation of leading experts in Russia, Kazakhstan, Kyrgyzstan, and Uzbekistan.
- Open Access
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 74-79
Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real-world clinical practice in Kazakhstan
Objective: to assess the efficacy and safety of olokizumab (OKZ) in routine clinical practice in patients with rheumatoid arthritis (RA) in Kazakhstan.Material and methods. A 24-week, single-center observational study included 26 RA patients with moderate to high disease activity according to DAS28. All patients received OKZ 64 mg subcutaneously every 4 weeks in combination with methotrexate. Disease activity according to DAS28- CRP was assessed at baseline and at weeks 4, 12, and 24.Results and discussion. Women comprised 88% of the study population. All patients were seropositive for rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies. The median age was 53 [24; 73] years, and the mean baseline DAS28-CRP score was 5.5±1.3. By week 24, a good or moderate response according to EULAR criteria was observed in 19 (73.0%) patients. DAS28-CRP remission was achieved in 50.0% of cases. OKZ was generally well tolerated, with no unexpected adverse events reported.Conclusion. This real-world study confirmed the efficacy and safety of OKZ in a predominantly Asian population of RA patients. The results are consistent with those of previous randomized controlled trials, supporting the use of OKZ in routine clinical practice as an effective and well-tolerated treatment option for RA.
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 74-79
Open AccessEfficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real-world clinical practice in Kazakhstan
Objective: to assess the efficacy and safety of olokizumab (OKZ) in routine clinical practice in patients with rheumatoid arthritis (RA) in Kazakhstan.Material and methods. A 24-week, single-center observational study included 26 RA patients with moderate to high disease activity according to DAS28. All patients received OKZ 64 mg subcutaneously every 4 weeks in combination with methotrexate. Disease activity according to DAS28- CRP was assessed at baseline and at weeks 4, 12, and 24.Results and discussion. Women comprised 88% of the study population. All patients were seropositive for rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies. The median age was 53 [24; 73] years, and the mean baseline DAS28-CRP score was 5.5±1.3. By week 24, a good or moderate response according to EULAR criteria was observed in 19 (73.0%) patients. DAS28-CRP remission was achieved in 50.0% of cases. OKZ was generally well tolerated, with no unexpected adverse events reported.Conclusion. This real-world study confirmed the efficacy and safety of OKZ in a predominantly Asian population of RA patients. The results are consistent with those of previous randomized controlled trials, supporting the use of OKZ in routine clinical practice as an effective and well-tolerated treatment option for RA.
- Open Access
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 7-18
Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies
One of the most promising approaches to depletion-restitution therapy is the development and use of drugs based on bispecific monoclonal antibodies (bsAbs). Therapeutic bsAbs are genetically engineered biological products (biologics) based on immunoglobulin molecules capable of simultaneously binding multiple antigens, making them a promising platform for novel drugs. A specific type of such agent, which incorporates at least two antigen-binding (Fab) fragments within a single immunoglobulin molecule – one targeting a specific cell-surface receptor and the other binding and activating to the CD3ε domain of CD3 molecule of the T-cell receptor complex – has been termed a bispecific T-cell engager (BiTE).Currently, BiTE molecules that engage effector cells of the humoral immune system are the most clinically advanced subclass of bsAbs. Their ability to deplete target cells in peripheral blood and tissues has been clearly demonstrated in the treatment of resistant hematological malignancies such as B-cell precursor acute lymphoblastic leukemia, various lymphoproliferative disorders, and plasma cell dyscrasias. Recent years have seen attempts to repurpose bsAbs for the treatment of refractory, prognostically unfavorable forms of systemic autoimmune rheumatic diseases (SARDs), supported by theoretical rationale, experimental evidence, and parallels with successful CAR-T cell therapy.Beyond BiTEs, the bsAb platform also enables development of biologics with extended pharmacokinetics, multi-cytokine targeting potential for synergistic suppression of inflammation, and checkpoint-directed modulation of targeted cell functional activity.Advantages such as standardized manufacturing, off-the-shelf availability, predictable pharmacokinetics (with a known and limited half-life), flexible dosing regimens enabling slow escalation of the dose, the possibility of individualizing treatment duration and dosing frequency, the feasibility of repeated treatment cycles, the option to discontinue therapy in case of adverse events, and the significantly lower cost of short low-dose treatment cycles compared to CAR-T cell therapy – all these make bsAb-based strategies a highly attractive priority for next-generation depletion-restitution therapies for SARDs.
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 7-18
Open AccessDepletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies
One of the most promising approaches to depletion-restitution therapy is the development and use of drugs based on bispecific monoclonal antibodies (bsAbs). Therapeutic bsAbs are genetically engineered biological products (biologics) based on immunoglobulin molecules capable of simultaneously binding multiple antigens, making them a promising platform for novel drugs. A specific type of such agent, which incorporates at least two antigen-binding (Fab) fragments within a single immunoglobulin molecule – one targeting a specific cell-surface receptor and the other binding and activating to the CD3ε domain of CD3 molecule of the T-cell receptor complex – has been termed a bispecific T-cell engager (BiTE).Currently, BiTE molecules that engage effector cells of the humoral immune system are the most clinically advanced subclass of bsAbs. Their ability to deplete target cells in peripheral blood and tissues has been clearly demonstrated in the treatment of resistant hematological malignancies such as B-cell precursor acute lymphoblastic leukemia, various lymphoproliferative disorders, and plasma cell dyscrasias. Recent years have seen attempts to repurpose bsAbs for the treatment of refractory, prognostically unfavorable forms of systemic autoimmune rheumatic diseases (SARDs), supported by theoretical rationale, experimental evidence, and parallels with successful CAR-T cell therapy.Beyond BiTEs, the bsAb platform also enables development of biologics with extended pharmacokinetics, multi-cytokine targeting potential for synergistic suppression of inflammation, and checkpoint-directed modulation of targeted cell functional activity.Advantages such as standardized manufacturing, off-the-shelf availability, predictable pharmacokinetics (with a known and limited half-life), flexible dosing regimens enabling slow escalation of the dose, the possibility of individualizing treatment duration and dosing frequency, the feasibility of repeated treatment cycles, the option to discontinue therapy in case of adverse events, and the significantly lower cost of short low-dose treatment cycles compared to CAR-T cell therapy – all these make bsAb-based strategies a highly attractive priority for next-generation depletion-restitution therapies for SARDs.
- 28 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70304
Biologic Therapy in Rheumatology: Analysis of Multidisciplinary Teams' Performance in Kazakhstan
- 28 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70304
Biologic Therapy in Rheumatology: Analysis of Multidisciplinary Teams' Performance in Kazakhstan